Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption

Objectives: Pancreatic enzyme replacement therapy (PERT) remains a backbone in the nutritional treatment of cystic fibrosis. Currently, there is a lack of an evidence-based tool that allows dose adjustment. To date, no studies have found an association between PERT dose and fat absorption. Therefore...

Full description

Bibliographic Details
Main Authors: Joaquim Calvo-Lerma, Sandra Martínez-Barona, Etna Masip, Victoria Fornés, Carmen Ribes-Koninckx
Format: Article
Language:English
Published: Aran Ediciones
Series:Revista Espanola de Enfermedades Digestivas
Subjects:
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017001000003&lng=en&tlng=en
id doaj-4457fe6e8ca04c328b5984c7c9e8e902
record_format Article
spelling doaj-4457fe6e8ca04c328b5984c7c9e8e9022020-11-24T21:11:43ZengAran EdicionesRevista Espanola de Enfermedades Digestivas1130-01081091068468910.17235/reed.2017.4951/2017S1130-01082017001000003Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorptionJoaquim Calvo-Lerma0Sandra Martínez-Barona1Etna Masip2Victoria Fornés3Carmen Ribes-Koninckx4La Fe Health Research InstituteLa Fe Health Research InstituteLa Fe Health Research InstituteLa Fe Health Research InstituteLa Fe Health Research InstituteObjectives: Pancreatic enzyme replacement therapy (PERT) remains a backbone in the nutritional treatment of cystic fibrosis. Currently, there is a lack of an evidence-based tool that allows dose adjustment. To date, no studies have found an association between PERT dose and fat absorption. Therefore, the aim of the study was to assess the influence of both the PERT dose and the variability in this dose on the coefficient of fat absorption (CFA). Methods: This is a retrospective longitudinal study of 16 pediatric patients (192 food records) with three consecutive visits to the hospital over a twelve-month period. Dietary fat intake and PERT were assessed via a four-day food record and fat content in stools was determined by means of a three-day stool sample collection. A beta regression model was built to explain the association between the CFA and the interaction between the PERT dose (lipase units [LU]/g dietary fat) and the variability in the PERT dose (standard deviation [SD]). Results: The coefficient of fat absorption increased with the PERT dose when the variability in the dose was low. In contrast, even at the highest PERT dose values, the CFA decreased when the variability was high. The confidence interval suggested an association, although the analysis was not statistically significant. Conclusion: The variability in the PERT dose adjustment should be taken into consideration when performing studies on PERT efficiency. A clinical goal should be the maintenance of a constant PERT dose rather than trying to obtain an optimal value.http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017001000003&lng=en&tlng=enCystic fibrosisEnzyme to substrate ratioPancreatic enzyme replacement therapy (PERT)Enzymatic supplementsCoefficient of fat absorption. Variability
collection DOAJ
language English
format Article
sources DOAJ
author Joaquim Calvo-Lerma
Sandra Martínez-Barona
Etna Masip
Victoria Fornés
Carmen Ribes-Koninckx
spellingShingle Joaquim Calvo-Lerma
Sandra Martínez-Barona
Etna Masip
Victoria Fornés
Carmen Ribes-Koninckx
Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption
Revista Espanola de Enfermedades Digestivas
Cystic fibrosis
Enzyme to substrate ratio
Pancreatic enzyme replacement therapy (PERT)
Enzymatic supplements
Coefficient of fat absorption. Variability
author_facet Joaquim Calvo-Lerma
Sandra Martínez-Barona
Etna Masip
Victoria Fornés
Carmen Ribes-Koninckx
author_sort Joaquim Calvo-Lerma
title Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption
title_short Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption
title_full Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption
title_fullStr Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption
title_full_unstemmed Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption
title_sort pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption
publisher Aran Ediciones
series Revista Espanola de Enfermedades Digestivas
issn 1130-0108
description Objectives: Pancreatic enzyme replacement therapy (PERT) remains a backbone in the nutritional treatment of cystic fibrosis. Currently, there is a lack of an evidence-based tool that allows dose adjustment. To date, no studies have found an association between PERT dose and fat absorption. Therefore, the aim of the study was to assess the influence of both the PERT dose and the variability in this dose on the coefficient of fat absorption (CFA). Methods: This is a retrospective longitudinal study of 16 pediatric patients (192 food records) with three consecutive visits to the hospital over a twelve-month period. Dietary fat intake and PERT were assessed via a four-day food record and fat content in stools was determined by means of a three-day stool sample collection. A beta regression model was built to explain the association between the CFA and the interaction between the PERT dose (lipase units [LU]/g dietary fat) and the variability in the PERT dose (standard deviation [SD]). Results: The coefficient of fat absorption increased with the PERT dose when the variability in the dose was low. In contrast, even at the highest PERT dose values, the CFA decreased when the variability was high. The confidence interval suggested an association, although the analysis was not statistically significant. Conclusion: The variability in the PERT dose adjustment should be taken into consideration when performing studies on PERT efficiency. A clinical goal should be the maintenance of a constant PERT dose rather than trying to obtain an optimal value.
topic Cystic fibrosis
Enzyme to substrate ratio
Pancreatic enzyme replacement therapy (PERT)
Enzymatic supplements
Coefficient of fat absorption. Variability
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017001000003&lng=en&tlng=en
work_keys_str_mv AT joaquimcalvolerma pancreaticenzymereplacementtherapyincysticfibrosisdosevariabilityandcoefficientoffatabsorption
AT sandramartinezbarona pancreaticenzymereplacementtherapyincysticfibrosisdosevariabilityandcoefficientoffatabsorption
AT etnamasip pancreaticenzymereplacementtherapyincysticfibrosisdosevariabilityandcoefficientoffatabsorption
AT victoriafornes pancreaticenzymereplacementtherapyincysticfibrosisdosevariabilityandcoefficientoffatabsorption
AT carmenribeskoninckx pancreaticenzymereplacementtherapyincysticfibrosisdosevariabilityandcoefficientoffatabsorption
_version_ 1716752942658224128